Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery
- 1st Edition - March 2, 2022
- Imprint: Elsevier
- Editor: Prashant Kesharwani
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 1 2 1 5 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 1 4 3 1 - 4
Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery is a comprehensive guide to PLGA nanoparticles for targeting various diseases, covering principles, formation… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePoly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery is a comprehensive guide to PLGA nanoparticles for targeting various diseases, covering principles, formation, characterization, applications, regulations and the latest advances. Sections introduce the fundamental aspects of PLGA nanoparticles for drug delivery, including properties, preparation methods, characterization, drug loading methods, and drug release mechanisms, along with a focus on applications. Application of PLGA nanoparticles for the treatment of cancer, inflammatory, cerebral, cardiovascular, and infectious diseases, as well as in regenerative medicine, photodynamic and photothermal therapy, and gene therapy, are all explained in detail.
The final chapters explore recent advances and regulatory aspects. This book is a valuable resource for researchers and advanced students across nanomedicine, polymer science, bio-based materials, chemistry, biomedicine, biotechnology, and materials engineering, as well as for industrial scientists and R&D professionals with an interest in nanoparticles for drug delivery, pharmaceutical formulations and regulations, and development of innovative biodegradable materials.
- Presents the fundamentals of PLGA nanoparticles, including properties, preparation, characterization, and biofate and cellular interactions
- Provides in-depth coverage of a broad range of specific applications of PLGA nanoparticles across disease treatment, regenerative medicine and therapeutic areas
- Offers a methodical approach to PLGA nanoparticles in drug delivery that is supported by data tables, illustrative figures and flowcharts
Researchers and advanced students in nanoparticles, nanomedicine, polymer science, bio-based materials, chemistry, biomedicine, biotechnology, and materials engineering, Scientists, R&D professionals, and clinicians with an interest in pharmaceutical formulations and regulations, and development of innovative plant-derived materials
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Part A: Synthesis and characterization of PLGA nanoparticles for drug delivery
- Chapter 1: History, introduction, and properties of PLGA as a drug delivery carrier
- Abstract
- 1: History
- 2: Introduction
- 3: Synthesis of poly(lactic-co-glycolic) acid
- 4: Properties of poly(lactic-co-glycolic) acid
- 5: Copolymers of poly(lactic-co-glycolic) acid
- 6: Surface modification of poly(lactic-co-glycolic) acid
- 7: Biodegradation of poly(lactic-co-glycolic) acid
- 8: Biosafety of poly(lactic-co-glycolic) acid
- References
- Chapter 2: Preparation and characterization of PLGA nanoparticles
- Abstract
- Part I: Preparation of PLGA nanoparticles
- Part II: Characterization of PLGA NPs
- References
- Chapter 3: Drug loading methods and drug release mechanisms of PLGA nanoparticles
- Abstract
- 1: Introduction
- 2: Drug loading methods of PLGA nanoparticles
- 3: Drug release mechanisms from PLGA nanoparticles
- References
- Chapter 4: Biofate and cellular interactions of PLGA nanoparticles
- Abstract
- 1: Introduction
- 2: PLGA and PLGA-based nanoparticles
- 3: Strategies with promise for improving drug delivery by PLGA-based nanoparticles
- 4: PLGA nanoparticles’ biodistribution, cell uptake, and cellular interactions
- 5: Toxicity assessment of PLGA nanoparticles
- 6: Biomedical applications of PLGA nanoparticles
- 7: Conclusions and perspectives
- References
- Part B: Application of PLGA nanoparticles in drug delivery
- Chapter 5: Targeting strategies using PLGA nanoparticles for efficient drug delivery
- Abstract
- 1: Introduction
- 2: PLGA nanoparticles
- 3: Targeting strategies
- 4: Conclusion
- References
- Further reading
- Chapter 6: Current progress in PLGA-based nanoparticles for treatment of cancer diseases
- Abstract
- 1: Introduction
- 2: Passive targeting
- 3: Active targeting
- 4: Conclusion
- References
- Chapter 7: PLGA-based nanoparticles for enhanced diagnosis and cancer therapy
- Abstract
- 1: Introduction
- 2: Physical and chemical properties of PLGA nanoparticles
- 3: Methods for drug-loaded PLGA nanoparticle synthesis
- 4: Surface modification of PLGA nanoparticles
- 5: Drug loading
- 6: Drug release mechanism from PLGA nanoparticles
- 7: Preclinical studies of PLGA-based nanoparticles in cancer
- 8: Shortcomings of PLGA nanoparticles
- 9: Conclusions and future outlook
- References
- Chapter 8: PLGA-based nanoparticles for the treatment of inflammatory diseases
- Abstract
- 1: Introduction
- 2: Methods of formation of PLGA-based nanoparticles
- 3: Physicochemical properties of PLGA-based nanoparticles
- 4: PLGA-based nanoparticles in targeting inflammatory diseases
- 5: Pitfalls and biosafety of PLGA-based nanoparticles
- 6: Clinical trials related to PLGA-based nanoparticles
- 7: Conclusions and future directions
- References
- Chapter 9: PLGA-based nanoparticles for treatment of cerebral diseases
- Abstract
- 1: Introduction
- 2: Strategies for enhanced brain drug delivery
- 3: Central nervous system disorders
- 4: Nanoparticles as carriers for drug delivery for cerebral diseases
- 5: Polymeric nanoparticles for drug delivery to the central nervous system
- 6: Formulation methods of polymeric nanoparticles
- 7: Parameters controlling CNS drug delivery
- 8: PLGA NPs as a brain drug delivery system
- 9: Conclusion
- References
- Chapter 10: PLGA nanoparticles for treatment of cardiovascular diseases
- Abstract
- 1: Introduction
- 2: Heart diseases and the importance of using delivery systems for their treatment
- 3: Methodologies for the preparation of PLGA nanoparticles used for heart treatment purposes
- 4: PLGA nanoparticles used for the treatment of heart disease
- 5: Future challenges for the use of PLGA nanoparticles in the treatment of the heart
- References
- Chapter 11: PLGA-based nanoparticles for treatment of infectious diseases
- Abstract
- 1: Introduction
- 2: Use of PLGA particles in the field of bacterial infections
- 3: Viral infections and the use of PLGA nanoparticles to treat them
- 4: PLGA nanoparticles-based delivery of antifungal drugs
- 5: Conclusion and outlook
- References
- Chapter 12: PLGA-based nanoparticles as regenerative medicine
- Abstract
- 1: Introduction
- 2: Nanoparticle platform for regenerative medicine
- 3: PLGA nanoparticle contribution as a drug delivery agent
- 4: Stem cells applications in regenerative medicines
- 5: Advancement in PLGA-based nanoparticles to improve the therapeutic value of regenerative medicines
- 6: Conclusion
- References
- Chapter 13: Photodynamic and photothermal therapy using PLGA nanoparticles
- Abstract
- Acknowledgments
- 1: History of phototherapies
- 2: Photodynamic therapy
- 3: PDT/PTT in multimodal therapies
- 4: Current challenges of PDT/PTT
- 5: PLGA in third-generation phototherapy systems
- 6: Areas of evolving use of PLGA in phototherapies
- 7: Phototherapies in the future
- References
- Chapter 14: Gene therapy using PLGA nanoparticles
- Abstract
- Acknowledgment
- 1: Introduction
- 2: Preparation of PLGA nanoparticles as a gene delivery tool
- 3: Role of nanoparticles in using gene therapy to treat various diseases
- 4: Use of PLGA nanoparticles for gene therapy
- 5: Conclusion
- References
- Part C: Recent advances and regulatory aspects in PLGA nanoparticles
- Chapter 15: Hybrid PLGA nanoparticles as advanced drug delivery and theranostic applications
- Abstract
- 1: Introduction
- 2: Hybrid nanoparticle systems
- 3: PLGA hybrid nanoparticles
- 4: Concluding remarks and future prospects
- References
- Chapter 16: Clinical translation of PLGA nanoparticles into market—From benchside to breakthrough therapy
- Abstract
- 1: Introduction
- 2: Translation of nanomedicine from bench to clinic
- 3: Conclusion
- References
- Chapter 17: Biological toxicity and environmental hazards associated with PLGA nanoparticles
- Abstract
- Acknowledgments
- 1: Introduction
- 2: PLGA nanoparticle delivery systems
- 3: PLGA nanoparticle formulation
- 4: Methods for screening cytotoxicity of PLGA nanoparticles
- 5: Environmental distribution of PLGA nanoparticles
- 6: Conclusions
- References
- Chapter 18: PLGA nanoparticles: Current uses and emerging trends
- Abstract
- Acknowledgments
- 1: Introduction
- 2: General aspects: Biodegradation, toxicity, and currently FDA-approved drugs
- 3: Scientific literature available on the production and applications of PLGA nanoparticles
- 4: PLGA nanoparticles from the perspective of patent documents
- 5: Comparison of scientific articles and patent applications on PLGA nanoparticles
- 6: Conclusion
- References
- Further reading
- Index
- Edition: 1
- Published: March 2, 2022
- Imprint: Elsevier
- No. of pages: 532
- Language: English
- Paperback ISBN: 9780323912150
- eBook ISBN: 9780323914314
PK
Prashant Kesharwani
Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.
Affiliations and expertise
Assistant Professor, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, 470003, IndiaRead Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery on ScienceDirect